Source: Behavioural Pharmacology. Unidade: FORP
Subjects: TRANSTORNOS PSICÓTICOS, FÁRMACOS (SISTEMA NERVOSO CENTRAL), ANTIPSICÓTICOS, FARMACOLOGIA, MODELOS ANIMAIS DE DOENÇAS
ABNT
ANDRADE, Yane C. P. et al. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behavioural Pharmacology, v. 32, n. 1, p. 2-8, 2021Tradução . . Disponível em: https://doi.org/10.1097/FBP.0000000000000595. Acesso em: 23 out. 2025.APA
Andrade, Y. C. P., Ropke, J., Viana, T. G., Fanelli, C., Minaldi, E., Batista, L. A., et al. (2021). Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. Behavioural Pharmacology, 32( 1), 2-8. doi:10.1097/FBP.0000000000000595NLM
Andrade YCP, Ropke J, Viana TG, Fanelli C, Minaldi E, Batista LA, Issy AC, Del Bel EA, Rodrigues LCM, Liégeois J-F, Moreira FA. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity [Internet]. Behavioural Pharmacology. 2021 ; 32( 1): 2-8.[citado 2025 out. 23 ] Available from: https://doi.org/10.1097/FBP.0000000000000595Vancouver
Andrade YCP, Ropke J, Viana TG, Fanelli C, Minaldi E, Batista LA, Issy AC, Del Bel EA, Rodrigues LCM, Liégeois J-F, Moreira FA. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity [Internet]. Behavioural Pharmacology. 2021 ; 32( 1): 2-8.[citado 2025 out. 23 ] Available from: https://doi.org/10.1097/FBP.0000000000000595